Inactive Instrument

Aerpio Pharmaceuticals

Equities

ARPO

US00810B1052

Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020

November 10, 2020 at 08:14 am EST

Aerpio Pharmaceuticals, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 5.861 million compared to USD 4.967 million a year ago. Net loss was USD 4.955 million compared to USD 4.648 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.11 a year ago. For the nine months, operating loss was USD 721,000 compared to USD 19.786 million a year ago. Net income was USD 402,000 compared to net loss of USD 18.824 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to basic loss per share from continuing operations of USD 0.46 a year ago.

Latest news about Aerpio Pharmaceuticals

Aadi Bioscience Completes Merger With Aerpio Pharmaceuticals; Shares Decline on Nasdaq Debut	21-08-27	MT
Aerpio Pharmaceuticals, Inc.(NasdaqCM:ARPO) dropped from NASDAQ Composite Index	21-08-27	CI
Aadi Bioscience, Inc. completed the acquisition of Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.	21-08-25	CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
North American Morning Briefing : Stock Futures -3-	21-07-09	DJ
AERPIO PHARMACEUTICALS : HC Wainwright Upgrades Aerpio Pharmaceuticals to Buy from Neutral on 'Transformative' Aadi Merger, Sets $22 Price Target	21-07-08	MT
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
Aerpio Pharmaceuticals : Earnings Flash (ARPO) AERPIO PHARMACEUTICALS Reports Q1 Loss $-0.09	21-05-17	MT
Aerpio Pharmaceuticals : Aadi Bioscience to Merge Into Combined Listed Company	21-05-17	MT
Aadi Bioscience, Inc. agreed to acquire Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.	21-05-16	CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-03-11	CI
Aerpio Pharmaceuticals Continues to Evaluate Strategic Alternatives	21-03-10	CI
Aerpio Pharmaceuticals : Quantum Leap Healthcare to Discontinue Testing of Aerpio Pharmaceutical's Razuprotafib in COVID Trial	21-03-05	MT
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’S Razuprotafib in I-Spy Covid Trial	21-03-05	CI
Aerpio Pharmaceuticals, Inc. Plans to Terminate Kevin Peters as Chief Scientific Officer and Chief Medical Officer	21-02-01	CI
After Hours Watch List Scorecard: ISR, TATT, ARPO	21-01-06	MT
Aerpio Pharmaceuticals Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial	21-01-06	CI
MT Newswires After Hours Watch List: ISR, TATT, ARPO	21-01-05	MT
Aerpio Pharmaceuticals : Pharma Starts Strategic Review To Boost Shareholder Value	21-01-05	MT
Aerpio Pharmaceuticals, Inc. Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial	21-01-05	CI
AERPIO PHARMACEUTICALS : HC Wainwright Adjusts Aerpio Pharmaceuticals' Price Target to $1.50 From $2, Keeps at Neutral	20-12-14	MT
Aerpio Pharmaceuticals, Inc. Announces Topline Results from Razuprotafib Glaucoma Phase 2 Trial	20-12-11	CI
Transcript : Aerpio Pharmaceuticals, Inc., Q3 2020 Earnings Call, Nov 10, 2020	20-11-10
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-10	CI
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19	20-10-26	CI

Chart Aerpio Pharmaceuticals

Duration

Period

More charts

Company Profile

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.

Sector

More about the company